Taysha Gene Therapies Inc (TSHA)
2.37
-0.11
(-4.44%)
USD |
NASDAQ |
May 08, 16:00
2.36
-0.01
(-0.42%)
After-Hours: 19:14
Taysha Gene Therapies Total Liabilities (Quarterly): 97.79M for Dec. 31, 2023
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 97.79M |
| September 30, 2023 | 244.88M |
| June 30, 2023 | 118.66M |
| March 31, 2023 | 116.55M |
| December 31, 2022 | 125.33M |
| September 30, 2022 | 100.34M |
| June 30, 2022 | 109.62M |
| March 31, 2022 | 115.25M |
| Date | Value |
|---|---|
| December 31, 2021 | 118.57M |
| September 30, 2021 | 100.65M |
| June 30, 2021 | 55.36M |
| March 31, 2021 | 19.96M |
| December 31, 2020 | 7.579M |
| September 30, 2020 | 11.62M |
| June 30, 2020 | 20.09M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
7.579M
Minimum
Dec 2020
244.88M
Maximum
Sep 2023
90.82M
Average
100.65M
Median
Sep 2021
Total Liabilities (Quarterly) Benchmarks
| Aquestive Therapeutics Inc | 163.90M |
| Lifecore Biomedical Inc | 256.99M |
| Relmada Therapeutics Inc | 12.19M |
| ACADIA Pharmaceuticals Inc | 317.20M |
| Cyclacel Pharmaceuticals Inc | 8.198M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 172.73M |
| Shareholders Equity (Quarterly) | 74.94M |
| Debt to Equity Ratio | 0.5406 |
| Current Ratio | 4.077 |
| Net Debt Paydown Yield | -0.14% |